Precision Medicine

How one family’s harrowing cancer journey sparked a record donation to MCW, aiming to fuel breakthrough research and bridge critical healthcare gaps in Wisconsin.

bioAffinity Technologies' new gene-silencing therapy kills common skin cancer cells in lab studies while leaving healthy cells untouched, hinting at a future without scars.

Praxis Precision Medicines' elsunersen earns Breakthrough Therapy status, signaling a major step toward the first disease-modifying treatment for SCN2A-DEE.

A new prostate cancer drug is emerging from a powerful alliance. We deconstruct the strategic rationale behind the deal, revealing a model for the future.

In a cooling life science real estate market, a major lease for advanced manufacturing highlights the rise of radiopharmaceuticals and Boston's enduring industrial might.

A new AI platform, born from its founder's own cancer battle, aims to give patients the tools to navigate complex treatments and advocate for their own care.

Israel's Biond Biologics hires Dr. Giovanni Selvaggi, a seasoned drug developer, as CMO. The move signals a strategic shift to accelerate its unique 'first-in-class' immunotherapies through late-stage trials.

Genialis's new BioBridge platform uses AI to de-risk the $137B flow of oncology drugs from China to the West, a critical test of resilience.

A new partnership between Pirche and Natera promises to connect pre-transplant risk analysis with post-transplant monitoring, ushering in an era of truly personalized care.

At BIO 2026, Fapon Group unveils a novel strategy combining T-cell engagers and in vivo CAR-T to target complex diseases. What does this mean for the future?

A new study reveals consumer interest in regenerative agriculture is surging, but it's driven by personal health and nutrition, not just environmentalism.

Kardium’s landmark FDA win and a new wave of innovators signal a biotech boom, cementing British Columbia's status as a global hub for health innovation.

Takeda is deploying Boltz's frontier AI across its labs, betting that AI agents can accelerate medicine by acting as a creative partner for scientists.

For years, CIDP patients faced limited options. Now, a wave of targeted therapies promises to transform treatment, sparking a multi-billion dollar market boom.

Quoin Pharma is making a bold bet, building a full commercial operation in Japan for its rare disease drug years before a potential launch. Is this the new model?

A new partnership between Charles River and Lilly TuneLab merges AI with nonclinical testing, aiming to fast-track new medicines and level the field for biotechs.

With a key webinar ahead, Arrowhead Pharma is showcasing a trio of gene-silencing drugs. Can its TRiM™ platform upend a multi-billion dollar cardiometabolic market?

A Taipei delegation at BIO 2026 signals Taiwan's strategic pivot from manufacturing to R&D, seeking global partners for its late-stage drugs and platforms.

German biotech Mallia Aesthetics reports impressive results for its hormone-free hair serum, but the real story lies in its resilient, science-first strategy.

After three decades, a new class of therapy for a rare liver disease lands in Singapore, rewriting the rules of care by targeting patient suffering, not just lab results.